[4] – ROTHBLATT MARTINE A (CIK 0001106578)

Rhea-AI Filing Summary

United Therapeutics (UTHR) reported insider transactions by its Chairperson & CEO (also a Director). On 10/13/2025 and 10/14/2025, the executive exercised 4,000 stock options each day at an exercise price of $120.26 per share (total 8,000 shares), and sold a total of 8,000 shares in multiple trades. Reported sale prices included $437.53, $441.26, $432.74, and weighted averages of $441.4 (range $441.085–$442.07) and $434.0077 (range $434.00–$434.145).

Following these transactions, direct holdings were 130 shares. Indirect holdings were reported as 166 shares by spouse and trusts holding 324,518, 258,117, 45,596, and 15,962 shares. Derivative securities beneficially owned following the reported transactions totaled 186,000 stock options.

The activity was conducted under a pre-arranged Rule 10b5-1 trading plan entered on May 2, 2025, which continues until the earlier of exhausting a 294,000-option tranche expiring March 15, 2026, or December 31, 2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

ROTHBLATT MARTINE A

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MD 20910

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairperson & CEO

3. Date of Earliest Transaction (Month/Day/Year)
10/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/13/2025		M(1)		4,000	A	$120.26	4,130	D
Common Stock	10/13/2025		S(1)		1,000	D	$437.53	3,130	D
Common Stock	10/13/2025		S(1)		3,000	D	$441.4(2)	130	D
Common Stock	10/14/2025		M(1)		4,000	A	$120.26	4,130	D
Common Stock	10/14/2025		S(1)		522	D	$432.74	3,608	D
Common Stock	10/14/2025		S(1)		1,478	D	$434.0077(3)	2,130	D
Common Stock	10/14/2025		S(1)		2,000	D	$441.26	130	D
Common Stock								166	I	by Spouse
Common Stock								324,518	I	by Trust(4)
Common Stock								258,117	I	by Trust(5)
Common Stock								45,596	I	by Trust(6)
Common Stock								15,962	I	by Trust(7)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$120.26	10/13/2025		M(1)			4,000	03/15/2016	03/15/2026	Common Stock	4,000	$0.00	190,000	D
Stock Option	$120.26	10/14/2025		M(1)			4,000	03/15/2016	03/15/2026	Common Stock	4,000	$0.00	186,000	D

Explanation of Responses:

1. This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on May 2, 2025. This plan will continue until the earlier of: (a) exhaustion of a tranche of 294,000 stock options that expire March 15, 2026; or (b) December 31, 2025.

2. This transaction was executed in multiple trades at prices ranging from $441.085 to $442.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $434.00 to $434.145. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.

5. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.

6. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.

7. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	10/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many UTHR shares did the executive sell in this Form 4?

The executive sold 8,000 shares across trades on 10/13/2025 and 10/14/2025.

What were the reported sale prices for the UTHR shares?

Sales occurred at $437.53, $441.26, $432.74, and weighted averages of $441.4 (range $441.085–$442.07) and $434.0077 (range $434.00–$434.145).

How many options did the UTHR executive exercise and at what price?

The executive exercised 8,000 options in total (4,000 on each date) at an exercise price of $120.26 per share.

What are the executive’s UTHR holdings after these transactions?

Direct holdings were 130 shares. Indirect holdings included 166 by spouse and trusts with 324,518, 258,117, 45,596, and 15,962 shares.

How many derivative securities remain after the reported activity?

Derivative securities beneficially owned following the transactions totaled 186,000 stock options.

Was the trading under a 10b5-1 plan and what are its terms?

Yes. The 10b5-1 plan was entered on May 2, 2025 and continues until the earlier of exhausting a 294,000-option tranche expiring March 15, 2026, or December 31, 2025.